Skip to main content

Gossamer Bio Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

GOSS$10.65+9.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets

(in thousands, except share and par value amounts)

December 31,
20232022
ASSETS
Current assets
Cash and cash equivalents$32,109$111,973
Marketable securities264,316143,705
Prepaid expenses and other current assets10,0946,202
Total current assets306,519261,880
Property and equipment, net1,6483,981
Operating lease right-of-use assets3,1315,909
Other assets618680
Total assets$311,916$272,450
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$5,526$1,459
Accrued research and development expenses7,77915,626
Current portion of long-term debt11,61311,613
Accrued expenses and other current liabilities26,68020,532
Total current liabilities51,59849,230
Long-term convertible senior notes196,591195,709
Long-term debt81411,988
Operating lease liabilities - long-term1443,446
Total liabilities249,147260,373
Commitments and contingencies (Note 11)
Stockholders' equity
Common stock, $0.0001 par value; 700,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 225,409,315 shares issued and outstanding as of December 31, 2023, and 94,478,405 shares issued and 94,423,181 shares outstanding as of December 31, 20222310
Additional paid-in capital1,275,1361,044,864
Accumulated deficit(1,212,040)(1,032,223)
Accumulated other comprehensive loss(350)(574)
Total stockholders' equity62,76912,077
Total liabilities and stockholders' equity$311,916$272,450
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.